60 Capsules Enzalutamide 40mg Entemide Prostate Cancer Medication

[Drug Name]
Generic Name:Enzalutamide Soft Capsules
Generic Name:Enzalutamide Soft Capsules

Generic Name:Enzalutamide Soft Capsules

Product Name: XTANDI

English Name: Enzalutamide Soft Capsules

Chinese Pinyin: Enzhalu'an Ruanjiaonang

[Indications]
This product is suitable for . inherit;">This product is indicated for

Adult patients with non-metastatic denuded resistant prostate cancer (NM-CRPC) with high risk of metastasis;

Treatment of Asymptomatic or Minimally Symptomatic Adult Patients with Metastatic Chemoresistant Prostate Cancer (CRPC) After Failure of male hormone Deprivation Therapy (ADT) and Not Receiving Chemotherapy.

[Dosage]
The drug should be used under the supervision of a physician experienced in the treatment of prostate cancer. inherit;">The medication should be used under the supervision of a specialist experienced in the treatment of prostate cancer.

dosages

The recommended dose is 160 mg of enzalutamide (four 40 mg softgels) taken orally once daily.

Non-surgically debrided patients should continue pharmacologic debridement with luteinizing hormone-releasing hormone (LHRH) analogs for the duration of treatment.

If a patient fails to take their medication on time, they should take the prescribed dose as soon as possible. If you miss a full day of medication, you should continue to take your usual daily dose the next day.

If a patient develops grade ≥3 toxicity or intolerable adverse reactions, the drug should be discontinued for 1 week or until symptoms subside to grade ≤2, and then restarted at the same dose or, if necessary, at a reduced dose (120 or 80 mg).

Concomitant use with potent CYP2C8 inhibitors

Co-administration with potent CYP2C8 inhibitors should be avoided if possible.

If patients must take a potent CYP2C8 inhibitor concomitantly, the dose of enzalutamide should be reduced to 80 mg once daily. After discontinuation of coadministration of a potent CYP2C8 inhibitor, the dose of enzalutamide should be restored to the pre-coadministration level.

liver damage

No dose adjustment is necessary in patients with mild, moderate, or severe hepatic impairment (Child-Pugh class A, B, or C, respectively).

renal insufficiency

No dose adjustment is necessary in patients with mild or moderate renal insufficiency. Use with caution in patients with severe renal insufficiency or end-stage renal disease (see PRECAUTIONS).

Children and adolescents

Enzalutamide is indicated for the treatment of denervation-resistant prostate cancer in adult men, but there is no experience with its use in children or adolescents.

autumn of one's years

No dose adjustment is required for elderly patients.

Mode of administration

This product is intended for oral administration. Do not chew, dissolve or open softgels. Take the entire capsule with water, with or without food.

[Adverse reactions]
The most common adverse reactions (≥10%) in randomized, placebo-controlled clinical trials of enanthate were. inherit;">The most common adverse reactions in randomized, placebo-controlled clinical trials (≥10%), and more common in the enzalutamide group (≥2% more common than in the placebo group), were malaise/fatigue, loss of appetite, hot flashes, joint pain, dizziness/nausea, hypertension, headache and weight loss.

[Storage]
Keep it under 25℃.